News & Updates

A single infusion of lovotibeglogene autotemcel (lovo-cel) resulted in near-complete resolution of vaso-occlusive events (VOEs) among patients with sickle cell disease (SCD), according to the combined analysis of phase I/II HGB-206 group C and phase III HGB-210 studies presented at ASH 2023.

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) – previously called nonalcoholic fatty liver disease (NAFLD) – but without  cirrhosis, who were treated with daily low-dose aspirin, had significant reductions in liver fat for 6 months in a new trial.

New drug applications approved by US FDA as of 16-31 December 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The use of fluvoxamine for outpatient treatment of mild-to-moderate COVID-19 falls short of reducing the duration of symptoms, as shown in the ACTIV-6 study.

Neutropenia following intra-arterial chemotherapy occurs more frequently than previously reported among children with retinoblastoma, with topotecan possibly linked to a risk increase, according to a study.

Statin therapy appears to mitigate the risk of venous thromboembolism associated with exogenous hormones, according to a study.

Prior to upper gastrointestinal endoscopy, premedication with pronase helps achieve better mucosal visibility and reduce flushing frequency and volume, reports a study. However, this strategy does not appear to improve lesion detection rates.

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.